<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>71-TRUE-MORPHINE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST OPIOID ANALGESICS" code="N01A-N02A" /></DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in cases of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>71-TRUE-MORPHINE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG1>
<DRUG2>
<DRUG name="METHADONE" rxcui="6813">
<ATC code="N02AC52" />
<ATC code="N07BC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of respiratory depression which can be fatal in case of overdose</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>71-TRUE-MORPHINE-ANTITUSSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TRUE MORPHINE ANTITUSSIVES" code="R0GDA0-002" /></DRUG1>
<DRUG2>
<CLASS name="AGONIST-ANTAGONIST OPIOIDS " code="NO2A-001" /></DRUG2>
<DESCRIPTION>Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
